​

Rhythm Pharmaceuticals (RYTM) Stock Forecast, Price Target & Predictions

OverviewRevenueOwnershipFinancialsChartTranscripts

RYTM Stock Forecast

Rhythm Pharmaceuticals (RYTM) stock forecast, based on 22 Wall Street analysts, predicts a 12-month average price target of $143.71, with a high of $160.00 and a low of $120.00. This represents a 41.17% increase from the last price of $101.80.

- $40 $80 $120 $160 $200 High: $160 Avg: $143.71 Low: $120 Last Closed Price: $101.8

RYTM Stock Rating

Rhythm Pharmaceuticals stock's rating consensus is Buy, based on 22 Wall Street analysts. The breakdown includes 0 Strong Buy (0.00%), 22 Buy (100.00%), 0 Hold (0.00%), 0 Sell (0.00%), and 0 Strong Sell (0.00%).

Buy
Total 22 0 22 Strong Sell Sell Hold Buy Strong Buy

RYTM Price Target Upside V Benchmarks

TypeNameUpside
StockRhythm Pharmaceuticals41.17%
SectorHealthcare Stocks 15.45%
IndustryBiotech Stocks 41.48%

Price Target Trends

1M3M12M
# Anlaysts1724
Avg Price Target$120.00$144.86$139.38
Last Closing Price$101.80$101.80$101.80
Upside/Downside17.88%42.30%36.92%
Ratings Trends
DateStrong BuyBuyHoldSellStrong SellTotal
Sep, 265102--17
Aug, 265101--16
Jul, 264111--16
Jun, 264111--16
May, 264111--16
Analyst Price Target Forecasts
DateAnalystCompanyPrice TargetPrice when PublishedPrice Target/Price when PublishedPrice Target/Last Closing Price
Aug 28, 2026David HoangDeutsche Bank$120.00$112.536.64%17.88%
Aug 05, 2026Canaccord Genuity$154.00$105.7845.59%51.28%
Aug 05, 2026National Bank$160.00$105.7851.26%57.17%
Jul 07, 2026RBC Capital$141.00$111.6826.25%38.51%
Jun 16, 2026Whitney IjemCanaccord Genuity$151.00$89.7068.34%48.33%
Jun 15, 2026Paul MatteisStifel Nicolaus$133.00$94.7340.40%30.65%
Jun 15, 2026Wells Fargo$155.00$88.3875.38%52.26%
May 07, 2026Canaccord Genuity$143.00$96.6148.02%40.47%
Mar 12, 2026Wells Fargo$143.00$90.0258.85%40.47%
Mar 03, 2026Dennis DingJefferies$125.00$89.5639.57%22.79%
Analyst Rating Forecasts
DateCompanyPrevious RatingNew RatingRating Change
Aug 28, 2026Deutsche BankHoldinitialise
Aug 05, 2026CitigroupBuyBuyhold
Aug 05, 2026CitigroupOutperformOutperformhold
Aug 05, 2026CitigroupMarket OutperformMarket Outperformhold
Jul 07, 2026RBC CapitalOutperformOutperformhold
Jun 17, 2026Cowen & Co.BuyBuyhold
Jun 15, 2026Wells FargoOverweightOverweighthold
Jun 03, 2026CitigroupMarket OutperformMarket Outperformhold
Mar 12, 2026Wells FargoOverweightOverweighthold
Mar 03, 2026JefferiesBuyBuyhold

Financial Forecast

EPS Forecast

$-5 $-2 $1 $4 $7 $10 Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-1.37$-3.51$-3.20$-4.34$-3.11---
Avg Forecast$-1.45$-3.53$-3.20$-4.12$-2.46$-0.75$2.25$6.28
High Forecast$-1.28$-3.23$-3.16$-3.82$-1.98$0.06$2.74$7.69
Low Forecast$-1.70$-4.09$-3.27$-4.39$-2.79$-2.04$1.22$5.49
Surprise %-5.52%-0.57%-5.34%26.42%---

Revenue Forecast

$0 $300M $600M $900M $1B $2B Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$3.15M$23.64M$77.43M$130.13M$189.76M---
Avg Forecast$3.03M$21.41M$78.80M$126.00M$181.85M$333.83M$602.63M$970.38M
High Forecast$3.44M$23.99M$80.69M$127.08M$208.91M$333.83M$602.63M$1.14B
Low Forecast$2.76M$20.00M$77.29M$125.06M$164.87M$333.83M$602.63M$876.95M
Surprise %4.19%10.43%-1.75%3.27%4.35%---

Net Income Forecast

$-300M $-150M $0 $150M $300M $450M Dec 21 Dec 22 Dec 23 Dec 24 Dec 25 Dec 26 Dec 27 Dec 28
Dec 21Dec 22Dec 23Dec 24Dec 25Dec 26Dec 27Dec 28
Reported$-69.61M$-181.12M$-184.68M$-260.60M$-201.92M---
Avg Forecast$-83.43M$-203.78M$-184.68M$-236.88M$-137.49M$-42.97M$114.18M$362.02M
High Forecast$-73.77M$-186.37M$-182.31M$-220.43M$-113.92M$3.61M$158.06M$443.67M
Low Forecast$-98.19M$-235.71M$-188.66M$-253.33M$-161.06M$-117.89M$70.31M$316.71M
Surprise %-16.57%-11.12%-10.02%46.86%---

RYTM Forecast FAQ

Is Rhythm Pharmaceuticals stock a buy?

Rhythm Pharmaceuticals stock has a consensus rating of Buy, based on 22 Wall Street analysts. The rating breakdown includes 0 Strong Buy, 22 Buy, 0 Hold, 0 Sell, and 0 Strong Sell, reflecting a consensus that Rhythm Pharmaceuticals is a favorable investment for most analysts.

What is Rhythm Pharmaceuticals's price target?

Rhythm Pharmaceuticals's price target, set by 22 Wall Street analysts, averages $143.71 over the next 12 months. The price target range spans from $120 at the low end to $160 at the high end, suggesting a potential 41.17% change from the previous closing price of $101.8.

How does Rhythm Pharmaceuticals stock forecast compare to its benchmarks?

Rhythm Pharmaceuticals's stock forecast shows a 41.17% upside, outperforming the average forecast for the healthcare stocks sector (15.45%) and underperforming the biotech stocks industry (41.48%).

What is the breakdown of analyst ratings for Rhythm Pharmaceuticals over the past three months?

  • September 2026: 29.41% Strong Buy, 58.82% Buy, 11.76% Hold, 0% Sell, 0% Strong Sell.
  • August 2026: 31.25% Strong Buy, 62.50% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.
  • July 2026: 25.00% Strong Buy, 68.75% Buy, 6.25% Hold, 0% Sell, 0% Strong Sell.

What is Rhythm Pharmaceuticals’s EPS forecast?

Rhythm Pharmaceuticals's average annual EPS forecast for its fiscal year ending in December 2026 is $-0.75, marking a -75.88% decrease from the reported $-3.11 in 2025. Estimates for the following years are $2.25 in 2027, and $6.28 in 2028.

What is Rhythm Pharmaceuticals’s revenue forecast?

Rhythm Pharmaceuticals's average annual revenue forecast for its fiscal year ending in December 2026 is $333.83M, reflecting a 75.92% increase from the reported $189.76M in 2025. The forecast for 2027 is $602.63M, and $970.38M for 2028.

What is Rhythm Pharmaceuticals’s net income forecast?

Rhythm Pharmaceuticals's net income forecast for the fiscal year ending in December 2026 stands at $-42.973M, representing a -78.72% decrease from the reported $-202M in 2025. Projections indicate $114.18M in 2027, and $362.02M in 2028.